Shenzhen Longshengming Pharmaceutical Technology Co., Ltd.
Home
About Us
  • Company Profile
  • Corporate Culture
Products
  • APIs
  • Intermediates
  • Preparations
  • Other Products
R&D
Quality
News
Contact Us
  • Contact Us
  • Join Us
News
  • 13 2026.04

    ABC Published in Nature Biotechnology

    Over the past decade, antibody–drug conjugates (ADCs) have emerged as a powerful targeted cancer therapy, delivering cytotoxic payloads to tumor cells with high specificity. ADCs have demonstrated strong clinical efficacy and safety across multiple tumor types.

    More
    ABC Published in Nature Biotechnology
  • 10 2026.04

    Merck's Imidazolid injection approved in China

    Merck today announced that its novel carbapenem/enzyme inhibitor combination formulation—imipenem for injection—has been approved by the National Medical Products Administration (NMPA). This product is indicated for the treatment of infections caused by susceptible Gram-negative bacteria in patients aged 18 years and older.

    More
    Merck's Imidazolid injection approved in China
  • 09 2025.03

    Harvard Study Shows Eating More Plant Protein and Less Meat Can Lower Heart Disease Risk

    Researchers at the Harvard T.H. Chan School of Public Health have found that replacing animal protein with plant protein is closely associated with a lower risk of cardiovascular disease (CVD) and coronary heart disease (CHD).

    More
    Harvard Study Shows Eating More Plant Protein  and Less Meat Can Lower Heart Disease Risk

Shenzhen Longshengming Pharmaceutical Technology Co., Ltd.

+86 188 1899 6566

andy@lsmpharma.com

Changhong Building, Keyuan Road,Nanshan District, Shenzhen, China

Copyright © 2026 Shenzhen Longshengming Pharmaceutical Technology Co., Ltd. All Rights Reserved.

WeChat QR code WeChat
WhatsApp QR code WhatsApp
Captcha